Time Course of Endometrium's Gene Expression Profiles Using Endometrial Tissue and Blood Samples
NCT ID: NCT06786273
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
62 participants
INTERVENTIONAL
2023-03-31
2024-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fertility in Healthy Premenopausal Women
NCT02772848
To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization
NCT01600794
Looking for a Blood Epigenetic Signature to Predict Female Infertility
NCT06098495
A Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women
NCT02868528
Application of Platelet-rich Plasma (PRP) in Reproductive Medicine
NCT06645379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P+3
Women who get their blood drawn and endometrial tissue biopsy taken at 3 days after progesterone administration starts.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
P+4
Women who get their blood drawn and endometrial tissue biopsy taken at 4 days after progesterone administration starts.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
P+5
Women who get their blood drawn and endometrial tissue biopsy taken at 5 days after progesterone administration starts.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
P+6
Women who get their blood drawn and endometrial tissue biopsy taken at 6 days after progesterone administration starts.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
P+7
Women who get their blood drawn and endometrial tissue biopsy taken at 7 days after progesterone administration starts.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Small RNA sequencing
The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 25-38 years old.
* BMI between 18 to 30.
* Endogenous progesterone (P4) level of \< 1 ng/mL prior to exogenous progesterone administration
Exclusion Criteria
* Women who are breastfeeding
* Have a history of pelvic inflammatory disease, reproductive tract-related diseases, sexually transmitted diseases, systemic diseases or endocrine diseases.
* History of major illness.
* Use of hormonal contraceptives or intrauterine devices in the past 3 months.
25 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inti Labs
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lee Women's Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS2-22033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.